494 related articles for article (PubMed ID: 31408463)
21. DEK is required for homologous recombination repair of DNA breaks.
Smith EA; Gole B; Willis NA; Soria R; Starnes LM; Krumpelbeck EF; Jegga AG; Ali AM; Guo H; Meetei AR; Andreassen PR; Kappes F; Vinnedge LM; Daniel JA; Scully R; Wiesmüller L; Wells SI
Sci Rep; 2017 Mar; 7():44662. PubMed ID: 28317934
[TBL] [Abstract][Full Text] [Related]
22. PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling.
van Beek L; McClay É; Patel S; Schimpl M; Spagnolo L; Maia de Oliveira T
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34066057
[TBL] [Abstract][Full Text] [Related]
23. Silencing DEK downregulates cervical cancer tumorigenesis and metastasis via the DEK/p-Ser9-GSK-3β/p-Tyr216-GSK-3β/β-catenin axis.
Xu X; Zou L; Yao Q; Zhang Y; Gan L; Tang L
Oncol Rep; 2017 Aug; 38(2):1035-1042. PubMed ID: 28627610
[TBL] [Abstract][Full Text] [Related]
24. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Jain PG; Patel BD
Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
[TBL] [Abstract][Full Text] [Related]
25. The Enigmatic Function of PARP1: From PARylation Activity to PAR Readers.
Kamaletdinova T; Fanaei-Kahrani Z; Wang ZQ
Cells; 2019 Dec; 8(12):. PubMed ID: 31842403
[TBL] [Abstract][Full Text] [Related]
26. DEK oncoprotein participates in heterochromatin replication via SUMO-dependent nuclear bodies.
Pierzynska-Mach A; Czada C; Vogel C; Gwosch E; Osswald X; Bartoschek D; Diaspro A; Kappes F; Ferrando-May E
J Cell Sci; 2023 Dec; 136(23):. PubMed ID: 37997922
[TBL] [Abstract][Full Text] [Related]
27. Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways.
Ghosh R; Roy S; Kamyab J; Danzter F; Franco S
DNA Repair (Amst); 2016 Sep; 45():56-62. PubMed ID: 27373144
[TBL] [Abstract][Full Text] [Related]
28. DEK over-expression promotes mitotic defects and micronucleus formation.
Matrka MC; Hennigan RF; Kappes F; DeLay ML; Lambert PF; Aronow BJ; Wells SI
Cell Cycle; 2015; 14(24):3939-53. PubMed ID: 25945971
[TBL] [Abstract][Full Text] [Related]
29. Role of the DEK oncogene in the development of squamous cell carcinoma.
Ishida K; Nakashima T; Shibata T; Hara A; Tomita H
Int J Clin Oncol; 2020 Sep; 25(9):1563-1569. PubMed ID: 32656741
[TBL] [Abstract][Full Text] [Related]
30. Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents.
Hu K; Wu W; Li Y; Lin L; Chen D; Yan H; Xiao X; Chen H; Chen Z; Zhang Y; Xu S; Guo Y; Koeffler HP; Song E; Yin D
EMBO Rep; 2019 May; 20(5):. PubMed ID: 30940648
[TBL] [Abstract][Full Text] [Related]
31. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
32. Deletion of the nuclear isoform of poly(ADP-ribose) glycohydrolase (PARG) reveals its function in DNA repair, genomic stability and tumorigenesis.
Min W; Cortes U; Herceg Z; Tong WM; Wang ZQ
Carcinogenesis; 2010 Dec; 31(12):2058-65. PubMed ID: 20926829
[TBL] [Abstract][Full Text] [Related]
33. Serine-linked PARP1 auto-modification controls PARP inhibitor response.
Prokhorova E; Zobel F; Smith R; Zentout S; Gibbs-Seymour I; Schützenhofer K; Peters A; Groslambert J; Zorzini V; Agnew T; Brognard J; Nielsen ML; Ahel D; Huet S; Suskiewicz MJ; Ahel I
Nat Commun; 2021 Jul; 12(1):4055. PubMed ID: 34210965
[TBL] [Abstract][Full Text] [Related]
34. DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis.
Mor-Vaknin N; Saha A; Legendre M; Carmona-Rivera C; Amin MA; Rabquer BJ; Gonzales-Hernandez MJ; Jorns J; Mohan S; Yalavarthi S; Pai DA; Angevine K; Almburg SJ; Knight JS; Adams BS; Koch AE; Fox DA; Engelke DR; Kaplan MJ; Markovitz DM
Nat Commun; 2017 Feb; 8():14252. PubMed ID: 28165452
[TBL] [Abstract][Full Text] [Related]
35. Secreted nuclear protein DEK regulates hematopoiesis through CXCR2 signaling.
Capitano ML; Mor-Vaknin N; Saha AK; Cooper S; Legendre M; Guo H; Contreras-Galindo R; Kappes F; Sartor MA; Lee CT; Huang X; Markovitz DM; Broxmeyer HE
J Clin Invest; 2019 May; 129(6):2555-2570. PubMed ID: 31107242
[TBL] [Abstract][Full Text] [Related]
36. The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity.
Kappes F; Waldmann T; Mathew V; Yu J; Zhang L; Khodadoust MS; Chinnaiyan AM; Luger K; Erhardt S; Schneider R; Markovitz DM
Genes Dev; 2011 Apr; 25(7):673-8. PubMed ID: 21460035
[TBL] [Abstract][Full Text] [Related]
37. Regulation of Rad52-dependent replication fork recovery through serine ADP-ribosylation of PolD3.
Richards F; Llorca-Cardenosa MJ; Langton J; Buch-Larsen SC; Shamkhi NF; Sharma AB; Nielsen ML; Lakin ND
Nat Commun; 2023 Jul; 14(1):4310. PubMed ID: 37463936
[TBL] [Abstract][Full Text] [Related]
38. Long noncoding RNA SOX2OT maintains the stemness of pancreatic cancer cells by regulating DEK via interacting with miR-200a/141.
Liu CS; Zhou Q; Zhang YD; Fu Y
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(5):2368-2379. PubMed ID: 32196588
[TBL] [Abstract][Full Text] [Related]
39. The DEK oncoprotein binds to highly and ubiquitously expressed genes with a dual role in their transcriptional regulation.
Sandén C; Järvstråt L; Lennartsson A; Brattås PL; Nilsson B; Gullberg U
Mol Cancer; 2014 Sep; 13():215. PubMed ID: 25216995
[TBL] [Abstract][Full Text] [Related]
40. PARP2 mediates branched poly ADP-ribosylation in response to DNA damage.
Chen Q; Kassab MA; Dantzer F; Yu X
Nat Commun; 2018 Aug; 9(1):3233. PubMed ID: 30104678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
